Comparative Pharmacology
Head-to-head clinical analysis: POMALYST versus THALOMID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POMALYST versus THALOMID.
POMALYST vs THALOMID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.
Thalidomide is an immunomodulatory agent with antiangiogenic and anti-inflammatory properties. Its exact mechanism is not fully understood, but it inhibits tumor necrosis factor-alpha (TNF-α) production, modulates cytokine activity, and suppresses angiogenesis by inhibiting basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF).
4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.
200 mg orally once daily, taken with water preferably at bedtime to reduce sedation; dose may be titrated up to 400 mg daily based on tolerability.
None Documented
None Documented
Terminal elimination half-life is approximately 7.5 hours in patients with multiple myeloma, allowing for once-daily dosing without accumulation at steady state.
Mean terminal elimination half-life is approximately 5-7 hours in healthy adults; may be prolonged to 12-18 hours in patients with hepatic impairment due to decreased metabolism.
Approximately 73% of radiolabeled pomalidomide is excreted in urine (primarily as metabolites, with <2% as unchanged drug) and 15% in feces. Renal clearance is the major elimination pathway.
Primarily renal: >80% of absorbed dose excreted unchanged in urine. Minor fecal elimination (<15%). No significant biliary excretion.
Category C
Category C
Immunomodulatory Agent
Immunomodulatory Agent